Vir Biotechnology (VIR) Cost of Revenue (2021 - 2025)
Historic Cost of Revenue for Vir Biotechnology (VIR) over the last 5 years, with Q2 2025 value amounting to $11000.0.
- Vir Biotechnology's Cost of Revenue fell 7884.62% to $11000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $745000.0, marking a year-over-year decrease of 2133.05%. This contributed to the annual value of $845000.0 for FY2024, which is 6943.94% down from last year.
- Latest data reveals that Vir Biotechnology reported Cost of Revenue of $11000.0 as of Q2 2025, which was down 7884.62% from $684000.0 recorded in Q4 2024.
- Over the past 5 years, Vir Biotechnology's Cost of Revenue peaked at $90.1 million during Q1 2022, and registered a low of $11000.0 during Q2 2025.
- Over the past 5 years, Vir Biotechnology's median Cost of Revenue value was $971000.0 (recorded in 2021), while the average stood at $13.5 million.
- Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 234064.69% in 2022, then tumbled by 9992.12% in 2023.
- Vir Biotechnology's Cost of Revenue (Quarter) stood at $56.9 million in 2021, then plummeted by 89.46% to $6.0 million in 2022, then crashed by 86.69% to $798000.0 in 2023, then decreased by 14.29% to $684000.0 in 2024, then crashed by 98.39% to $11000.0 in 2025.
- Its last three reported values are $11000.0 in Q2 2025, $684000.0 for Q4 2024, and $50000.0 during Q3 2024.